Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of ...

Mangaluru: The tender process for setting up Keonics Software Park near Blue Berry Hills in Mangaluru will commence by the ...

On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Panel discussions spotlight key growth areas The event featured four high-impact panel discussions, each exploring a critical ...

Nearly a year after we launched AI Overviews in the US, we continue to see that usage growth is increasing,” Sundar Pichai said during Alphabet's Q1 earnings call.

With artificial intelligence (AI) transforming industries around the world at lightning speed, the need for experts in the ...

ABA Centers tops the FT’s sixth annual ranking, compiled with Statista, of the region’s most rapidly growing companies ...

As enterprises move beyond experimentation toward production AI systems, tools that simplify the creation of continually ...

In recent years, off-grid regions have gained increasing attention regarding their energy needs, with solar energy emerging as a key driver of energy transformation. By the end of 2024, global ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...